按產品類型、治療用途和地區分類的生物製藥市場

Biopharmaceuticals Market, By Product Type, By Therapeutic Application, and By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計 2025 年生物製藥市場規模為 4,582.1 億美元，到 2032 年將達到 7,552.6 億美元，2025 年至 2032 年的複合年成長率為 7.4%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	4582.1億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	7.40%	2032年價值預測	7552.6億美元

生物製藥是由生物來源製造、萃取或半合成的治療藥物。生物製藥涵蓋範圍廣泛，例如疫苗、治療性蛋白質、血液及血液成分以及組織。生物製藥是現代科學最尖端、最傑出的成就之一。

市場動態：

慢性病、感染疾病和神經系統疾病負擔的增加、老年人口的增加、研發的增加以及 COVID-19（大流行）的爆發是預計將促進全球生物製藥市場成長的主要因素。

例如，Phanes Therapeutics, Inc. 於2022年10月獲得美國食品藥物管理局 (FDA) 的批准，啟動PT217的I期臨床試驗。 PT217是一種正在研究的抗Delta樣配體3 (DLL3)/抗分化簇47 (CD47)雙特異性抗體，用於治療美國食品藥物管理局(SCLC) 和其他神經內分泌癌患者。 PT217最近獲得了FDA授予的治療SCLC的孤兒藥資格。

本研究的主要特點

本報告對全球生物製藥市場進行了詳細分析，並以 2024 年為基準年，給出了 2025 年至 2032 年預測期內的市場規模和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球生物製藥市場的主要企業概況。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興車型、市場擴張和行銷策略做出明智的決策。
全球生物製藥市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球生物製藥市場所使用的各種策略矩陣來促進決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 458.21 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	7.40%	2032 Value Projection:	USD 755.26 Bn

A biopharmaceutical is a therapeutic drug manufactured in, extracted from, or semi-synthesized from biological sources. Biopharmaceuticals include a wide range of products such as vaccines, therapeutic proteins, blood and blood components, tissues, etc. Biopharmaceuticals are among the most sophisticated and elegant achievements of modern science.

Market Dynamics:

Increasing burden of chronic, infectious, and neurological diseases, growing geriatric population, increase in research and development (R&D), and outbreak of COVID-19 (pandemic) are major factors expected to augment the growth of the global biopharmaceuticals market.

For instance, in October 2022, Phanes Therapeutics, Inc. received clearance from the US Food and Drug Administration (FDA) to commence Phase I studies with PT217, its anti-Delta-like ligand 3 (DLL3)/anti-Cluster of differentiation 47 (CD47) bispecific antibody being developed for patients with small cell lung cancer (SCLC) and other neuroendocrine cancer. PT217 recently been granted an orphan drug designation by the FDA for the treatment of SCLC.

Key features of the study:

This report provides in-depth analysis of the global biopharmaceuticals market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global biopharmaceuticals market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Amgen Inc., GlaxoSmithKline PLC, Pfizer Inc., Novo Nordisk AS, Novartis AG, Johnson & Johnson, Eli Lilly and Company, Bristol-Myers Squibb Company, Abbvie Inc., and F. Hoffmann-La Roche Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global biopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biopharmaceuticals market.

Detailed Segmentation:

Global Biopharmaceuticals Market, By Product Type:
- Monoclonal Antibodies
- Recombinant Growth Factors
- Purified Proteins
- Recombinant Proteins
- Recombinant Hormones
- Vaccines
- Recombinant Enzymes
- Cell and Gene Therapies
- Synthetic Immunomodulators
- Other Product Types
Global Biopharmaceuticals Market, By Therapeutic Application:
- Oncology
- Inflammatory and Infectious Diseases
- Autoimmune Disorders
- Metabolic Disorders
- Hormonal Disorders
- Cardiovascular Diseases
- Neurological Diseases
- Other Diseases
Global Biopharmaceuticals Market, By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Company Profiles:
- Amgen Inc.
- Abbvie Inc.
- GlaxoSmithKline PLC
- Pfizer Inc.
- Novo Nordisk AS
- Novartis AG
- Johnson & Johnson
- Eli Lilly and Company
- Bristol-Myers Squibb Company
- F.Hoffmann-La Roche Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Therapeutic Application
- Market Snapshot, By Geography
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Rise in patient pool and growing geriatric population
- High-end manufacturing requirements
- The outbreak of COVID-19 (global pandemic)
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Biopharmaceuticals Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Biopharmaceuticals Market, By Product Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Recombinant Growth Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Purified Proteins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Recombinant Proteins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Recombinant Hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Recombinant Enzymes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Cell and Gene Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Synthetic Immunomodulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Other Product Types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Biopharmaceuticals Market, By Therapeutic Application, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Inflammatory and Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Autoimmune Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Metabolic Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Hormonal Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Cardiovascular Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Neurological Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Other Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Biopharmaceuticals Market, By Geography, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)
Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Application, 2020-2032,(US$ Bn)

8. Competitive Landscape

Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Abbvie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novo Nordisk AS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views